Acid Phosphatases

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 165-180

  Kaija, Helena ^a   Patrikainen, Lila O T ^a   Alatalo, Sari L ^b   Väänänen, H Kalervo ^c   Vihko, Pirkko T ^d  

^a UNIVERSITY OF OULU   (Finland)

^b FINNISH RED CROSS BLOOD SERVICE   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882541757     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50011-X     Document Type: Chapter

References (151)

1. Vincent J.B., Crowder M.W., Averill B.A. Hydrolysis of phosphate monoesters: a biological problem with multiple chemical solution. Trends. Biochem. Sci. 1992, 17:105-110.
2. Lohse D.L., Denu J.M., Dixon J.E. Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase1. Structure 1995, 3:987-990.
3. Barford D., Das A.K., Egloff M.P. The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu. Rev. Biophys. Biomol. Struct. 1998, 27:133-164.
4. Li C.Y., Yam L.T., Lam K.W. Studies of acid phosphatase isoenzymes in human leukocytes demonstration of isoenzyme cell specificity. J. Histochem. Cytochem. 1970, 18:901-910.
5. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
6. Hashimoto N., Feener E.P., Zhang W.R., Goldstein B.J. J. Biol. Chem. 1992, 267:13811-138142.
7. Jackson S.P. Insulin receptor protein-tyrosine phosphatases. Leukocyte common antigen-related phosphatase rapidly deactivates the insulin receptor kinase by preferential dephosphorylation of the receptor regulatory domain. Trends. Cell. Biol. 1992, 2:104-108.
8. Li C.Y., Yam L.T., Lam K.W. Acid phosphatase isoenzyme in human leukocytes in normal and pathologic conditions. J. Histochem. Cytochem. 1970, 18(7):473-481.
9. Lau K.H., Freeman T.K., Baylink D.J. Purification and characterization of an acid phosphatase that displays phosphotyrosyl-protein phosphatase activity from bovine cortical bone matrix. J. Biol. Chem. 1987, 262(3):1389-1397.
10. Lam K.W., Yam L.T. Biochemical characterization of the tartrate-resistant acid phosphatase of human spleen with leukemic reticuloendotheliosis as a pyrophosphatase. Clin. Chem. 1977, 23(1):89-94.
11. Halleen J., Hentunen T.A., Hellman J., Väänänen H.K. Tartrate-resistant acid phosphatase from human bone: purification and development of an immunoassay. J. Bone. Miner. Res. 1996, 11(10):1444-1452.
12. Anderson T.R., Toverud S.U. Purification and characterization of purple acid phosphatase from developing rat bone. Arch. Biochem. Biophys. 1986, 247(1):131-139.
13. Ek-Rylander B., Bergman T., Andersson G. Characterization of a tartrate-resistant acid phosphatase (ATPase) from rat bone: hydrodynamic properties and N-terminal amino acid sequence. J. Bone. Miner. Res. 1991, 6(4):365-373.
14. Ljusberg J., Ek-Rylander B., Andersson G. Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases. Biochem. J. 1999, 343(Pt 1):63-69.
15. Funhoff E.G., Ljusberg J., Wang Y., Andersson G., Averill B.A. Mutational analysis of the interaction between active site residues and the loop region in mammalian purple acid phosphatases. Biochemistry 2001, 40(38):11614-11622.
16. Yam L.T., Li C.Y., Lam K.W. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N. Engl. J. Med. 1971, 284(7):357-360.
17. Väänänen H.K., Karhukorpi E.K., Sundquist K., Wallmark B., Roininen I., Hentunen T., Tuukkanen J., Lakkakorpi P. Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in, the ruffled borders of osteoclasts. J. Cell Biol. 1990, 111(3):1305-1311.
18. Clark S.A., Ambrose W.W., Anderson T.R., Terrell R.S., Toverud S.U. Ultrastructural localization of tartrate-resistant, purple acid phosphatase in rat osteoclasts by histochemistry and immunocytochemistry. J. Bone Miner. Res. 1989, 4(3):399-405.
19. Halleen J.M., Räisänen S., Salo J.J., Reddy S.V., Roodman G.D., Hentunen T.A., Lehenkari P.P., Kaija H., Vihko P., Väänänen H.K. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrateresistant acid phosphatase. J. Biol. Chem. 1999, 274(33):22907-22910.
20. Reinholt F.P., Widholm S.M., Ek-Rylander B., Andersson G. Ultrastructural localization of a tartrate-resistant acid ATPase in bone. J. Bone Miner. Res. 1990, 5(10):1055-1061.
21. Räisänen S.R., Halleen J., Parikka V., Väänänen H.K. Tartrate-resistant acid phosphatase facilitates hydroxyl radical formation and colocalizes with phagocytosed Staphylococcus aureus in alveolar macrophages. Biochem. Biophys. Res. Commun. 2001, 288(1):142-150.
22. Sheu T.J., Schwarz E.M., Martinez D.A., O'Keefe R.J., Rosier R.N., Zuscik M.J., Puzas J.E. A phage display technique identifies a novel regulator of cell differentiation. J. Biol. Chem. 2003, 278(1):438-443.
23. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif. Tissue Int. 1982, 34(3):285-290.
24. Brehme C.S., Roman S., Shaffer J., Wolfert R. Tartrate-resistant acid phosphatase forms complexes with alpha2-macroglobulin in serum. J. Bone Miner. Res. 1999, 14(2):311-318.
25. Lau K.H., Onishi T., Wergedal J.E., Singer F.R., Baylink D.J. Characterization and assay of tartrate-resistant acid phosphatase activity in serum potential use to assess bone resorption. Clin. Chem. 1987, 33(4):458-462.
26. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., Väänänen H.K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J. Bone Miner. Res. 2000, 15(7):1337-1345.
27. Sträter N., Klabunde T., Tucker P., Witzel H., Krebs B. Crystal structure of a purple acid phosphatase containing a dinuclear Fe(III)-Zn(II) active site. Science 1995, 268(5216):1489-1492.
28. Guddat L.W., McAlpine A.S., Hume D., Hamilton S., de Jersey J., Martin J.L. Crystal structure of mammalian purple acid phosphatase. Arch. Biochem. Biophys. 1999, 352(1):97-102.
29. Lindqvist Y., Johansson E., Kaija H., Vihko P., Schneider G. Three-dimensional structure of a mammalian purple acid phosphatase at 2.2. A resolution with a mu-(hydr)oxo bridged di-iron center. J. Mol. Biol. 1999, 291(1):135-147.
30. Uppenberg J., Lindqvist F., Svensson C., Ek-Rylander B., Andersson G. Crystal structure of a mammalian purple acid phosphatase. J. Mol. Biol. 1999, 290(1):201-211.
31. Davis J.C., Averill B.A. Evidence for a spin-coupled binuclear iron unit at the active site of the purple acid phosphatase from beef spleen. Proc. Natl. Acad. Sci. USA 1982, 79(15):4623-4627.
32. Vincent J.B., Averill B.A. Sequence homology between purple acid phosphatases and phosphoprotein phosphatases. Are phosphoprotein phosphatases metalloproteins containing oxide-bridged dinuclear metal centers. FEBS Lett 1990, 263(2):265-268.
33. Kaija H., Jia J., Lindqvist Y., Andersson G., Vihko P. Tartrate-resistant bone acid phosphatase: large-scale production and purification of the recombinant enzyme, characterization, and crystallization. J. Bone Miner. Res. 1999, 14(3):424-430.
34. Baumbach G.A., Saunders P.T., Bazer F.W., Roberts R.M. Uteroferrin has N-asparagine-linked high-mannose-type oligosaccharides that contain mannose 6-phosphate. Proc. Natl. Acad. Sci. USA 1984, 81(10):2985-2989.
35. Zhang Z.Y., Wang Y., Wu L., Fauman E.B., Stuckey J.A., Schubert H.L., Saper M.A., Dixon J.E. The Cys(X)5Arg catalytic motif in phosphoester hydrolysis. Biochemistry 1994, 33(51):15266-15270.
36. Lam W.K., Eastlund D.T., Li C.Y., Yam L.T. Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin. Chem. 1978, 24(7):1105-1108.
37. Janckila A.J., Neustadt D.H., Nakasato Y.R., Halleen J.M., Hentunen T., Yam L.T. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin. Chim Acta 2002, 320(1-2):49-58.
38. Halleen J.M., Alatalo S.L., Janckila A.J., Woitge H.W., Seibel M.J., Väänänen H.K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin. Chem. 2001, 47(3):597-600.
39. Janckila A.J., Takahashi K., Sun S.Z., Yam L.T. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin. Chem. 2001, 47(1):74-80.
40. Walsh N.C., Cahill M., Caminci P., Kawai J., Okazaki Y., Hayashizaki Y., Hume D.A., Cassady A.I. Multiple tissue-specific promoters control expression of the murine tartrate-resistant acid phosphatase gene. Gene 2003, 307:111-123.
41. Reddy S.V., Scarcez T., Windle J.J., Leach R.J., Hundley J.E., Chirgwin J.M., Chou J.Y., Roodman G.D. Cloning and characterization of the 5?-flanking region of the mouse tartrate-resistant acid phosphatase gene. J. Bone. Miner. Res. 1993, 8(10):1263-1270.
42. Simmen R.C., Srinivas V., Roberts R.M. CDNA sequence, gene organization, and progesterone induction of mRNA for uteroferrin, a porcine uterine iron transport protein. DNA 1989, 8(8):543-554.
43. Alcantara O., Reddy S.V., Roodman G.D., Boldt D.H. Inhibition of tartrate-resistant acid phosphatase gene expression by hemin and protoporhyrin IX Identification of a hemin-responsive inhibitor of transcription. Blood 1996, 88(6):2288-2297.
44. Reddy S.V., Alcantara O., Roodman G.D., Boldt D.H. Inhibition of tartrate-resistant acid phosphatase gene expression by hemin and protoporphyrin IX. Identification of a hemin-responsive inhibitor of transcription. Blood 1996, 88(6):2288-2297.
45. Fleckenstein E.C., Dirks W.G., Drexler H.G. The human tartrate-resistant acid phosphatase (TRAP): involvement of the hemin responsive elements (HRE) in transcriptional regulation. Leuk Lymphoma 2000, 36(5-6):603-612.
46. Luchin A., Suchting S., Merson T., Rosol T.J., Hume D.A., Cassady A.I., Ostrowski M.C. Genetic and physical interactions between Microphthalmia transcription factor and PU. I are necessary for osteoclast gene expression and differentiation. J. Biol. Chem. 2001, 276(39):36703-36710.
47. Liu Y., Shi Z., Silveira A., Liu J., Sawadogo M., Yang H., Feng X. Involvement of upstream stimulatory factors 1 and 2 in RANKL-induced transcription of tartrate-resistant acid phosphatase gene during osteoclast differentiation. J. Biol. Chem. 2003, 278(23):20603-20611.
48. Halleen J.M., Kaija H., Stepan J.J., Vihko P., Väänänen H.K. Studies on the protein tyrosine phosphatase activity of tartrate-resistant acid phosphatase. Arch. Biochem. Biophys. 1998, 352(1):97-102.
49. Ek-Rylander B., Flores M., Wendel M., Heinegard D., Andersson G. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J. Biol. Chem. 1994, 269(21):14853-14856.
50. Janckila A.J., Woodford T.A., Lam K.W., Li C.Y., Yam L. Protein-tyrosine phosphatase activity of hairy cell tartrate-resistant acid phosphatase. Leukemia 1992, 6(3):199-203.
51. Schlosnagle D.C., Sander E.G., Bazer F.W., Roberts R.M. Requirement of an essential thiol group and ferric iron for the activity of the progesterone-induced porcine uterine purple phosphatase. J. Biol. Chem. 1976, 251(15):4680-4685.
52. Klabünde T., Sträter N., Frohlich R., Witzel H., Krebs B. Mechanism of Fe(III)-Zn(II) purple acid phosphatase based on crystal structures. J. Mol. Biol. 1996, 259(15):4680-4685.
53. Klabünde T., Sträter N., Ronhlich R., Witzel H., Krebs B. Mechanism of Fe(III)-Zn(II) purple acid phosphatase based on crystal structures. J. Mol. Biol. 1996, 259(4):737-748.
54. Wang X., Randall C.R., True A.E., Que L. X-ray absorption spectroscopic studies of the FeZn derivative of uteroferrin. Biochemistry 1996, 35(44):13946-13954.
55. Merkx M., Pinkse M.W., Averill B.A. Evidence for nonbridged coordination of p-nitrophenyl phosphate to the dinuclear Fe(III)-M(II) center in bovine spleen purple acid phosphatase during enzymatic turnover. Biochemistry 1999, 38(31):9914-9925.
56. Flores M.E., Norgard M., Heinegard D., Reinholt F.P., Andersson G. RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone sialoprotein, and fibronectin. Exp. Cell. Res. 1992, 201(2):526-530.
57. Sibille J.C., Doi K., Aisen P. Hydroxyl radical formation and iron-binding proteins. Stimulation by the purple acid phosphatases. J. Biol. Chem. 1987, 262(1):59-62.
58. Hayman A.R., Cox T.M. Purple acid phosphatase of the human macrophage and osteoclast. Characterization, molecular properties, and crystallization of the recombinant di-iron-oxo protein secreted by baculovirus-infected insect cells. J. Biol. Chem. 1994, 269(2):1294-1300.
59. Davies K.J., Delsignore M.E. Protein damage and degradation by oxygen radicals. III. Modification of secondary and tertiary structure. J. Biol. Chem. 1987, 262(20):9908-9913.
60. Garrett I.R., Boyce B.F., Oreffo R.O., Bonewald L., Poser J., Mundy G.R. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J. Clin. Invest. 1990, 85(3):632-639.
61. Bune A.J., Hayman A.R., Evans M.J., Cox T.M. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disordered macrophage inflammatory responses and reduced clearance of the pathogen. Staphylococcus aureus. Immunology 2001, 102(1):103-113.
62. Kaija H., Alatalo S.L., Halleen J.M., Lindqvist Y., Schneider G., Väänänen H.K., Kihko P. Phosphatase and oxygen radical-generating activities of mammalian purple acid phosphatase are functionally independent. Biochem. Biophys. Res. Commun. 2002, 292(1):128-132.
63. Beck J.L., Durack M.C., Hamilton S.E., de Jersey J. Irreversible inactivation of purple acid phosphatase by hydrogen peroxide and ascorbate. J. Inorg. Biochem. 1999, 73(4):245-252.
64. Hayman A.R., Jones S.J., Boyde A., Foster D., Colledge W.H., Carlton M.B., Evans M.J., Cox T.M. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development 1996, 122(10):3151-3162.
65. Angel N.Z., Walsh N., Forwood M.R., Ostrowski M.C., Cassady A.I., Hume D.A. Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J. Bone Miner. Res. 2000, 15(1):103-110.
66. Hollberg K., Hultenby K., Hayman A., Cox T., Andersson G. Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. Exp. Cell. Res. 2002, 279(2):227-238.
67. Suter A., Everts V., Boyde A., Jones S.J., Lullmann-Rauch R., Hartmann D., Hayman A.R., Cox T.M., Evans M.J., Meister T., von Figura K., Saftig P. Overlapping functions of lysosomal acid phosphatase (LAP) and tartrate-resistant acid phosphatase (Acp5) revealed by doubly deficient mice. Development 2001, 128(23):4899-4910.
68. Räisänen S. Differential effects of carbonic anhydrase III and tartrate-resistant acid phosphatase on intracellular radical balance. Thesis 2004, 1-93. Institute of Biomedicine, Department of Anatomy, Turku, University of Turku.
69. Saftig P., Hartmann D., Lullmann-Rauch R., Wolff J., Evers M., Koster A., Hetman M., von Figura K., Peters C. Mice deficient in lysosomal acid phosphatase develop lysosomal storage in the kidney and central nervous system. J. Biol. Chem. 1997, 272(30):18628-18635.
70. Janckila A.J., Takahashi K., Sun S.Z., Yam L.T. Naphthol-ASB1 phosphate as a preferred substrate for tartrate-resistant acid phosphatase isoform 5b. J. Bone. Miner. Res. 2001, 16(4):788-793.
71. Nakanishi M., Yoh K., Miura T., Ohasi T., Rai S.K., Uchida K. Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. Clin. Chem. 2000, 46(4):469-473.
72. Halleen J.M., Karp M., Viloma S., Laaksonen P., Hellman J., Käkönen S.M., Stepan J.J., Holmes S., Väänänen H., Pettersson K. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies. J. Bone. Miner. Res. 1999, 14(3):464-469.
73. Stepan J.J., Silinkova-Malkova E., Havranek T., Formankova J., Zichova M., Lachmanova J., Strakova M., Broulik P., Pacovsky V. Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin. Chim. Acta. 1983, 133(2):189-200.
74. Nakanishi M., Yoh K., Uchida K., Maruo S., Rai S.K., Matsuoka A. Clinical usefulness of serum tartrate-resistant fluoride-sensitive acid phosphatase activity in evaluating bone turnover. J. Bone Miner Metab. 1999, 17(2):125-130.
75. Chu P., Chao T.Y., Lin Y.F., Janckila A.J., Yam L.T. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am. J. Kidney Dis. 2003, 41(5):1052-1059.
76. Cheng S., Tylavsky F., Kröger H., Kärkkäinen M., Lyytikäinen A., Koistinen A., Mahonen A., Alen M., Halleen J., Väänänen K., Lamberg-Allardt C. Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls. Am. J. Clin. Nutr. 2003, 78(3):485-492.
77. Terpos E., de la Fuente J., Szydlo R., Hatjiharissi E., Viniou N., Meletis J., Yataganas X., Goldman J.M., Rahemtulla A. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int. J. Cancer. 2003, 106(3):455-457.
78. Gerdhem P., Ivaska K.K., Alatalo S.L., Hallee J.M., Hellman J., Isaksson A., Pettersson K., Väänänen H.K., Kesson K., Obrant K.J. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J. Bone Miner. Res. 2004, 19(3):386-393.
79. Nakasato Y.R., Janckila A.J., Halleen J.M., Väänänen H.K., Walton S.P., Yam L.T. Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin. Chem. 1999, 45(12):2150-2157.
80. Derechin M., Ostrowski W., Galka M., Barnard E.A. Acid phosphomonoesterase of human prostate: molecular weight dissociation and chemical composition. Biochim. Biophys. Acta. 1971, 250:143-154.
81. Ostrowski W., Bhargava A.K., Dziembor E., Gizler M., Gryszkiewicz J.T., Barnard E.A. Acid phosphomonoesterase of human prostate. Carbohydrate content and optical properties. Biochim. Biophys. Acat. 1976, 453:262-269.
82. Risley M.J., van Etten R.L. Structures of the carbohydrate moieties of human prostatic acid phosphatase elucidated by 1H nuclear magnetic resonance spectroscopy. Arch. Biochem. Biophys. 1987, 258:404-412.
83. Hakalahti L., Vihko P., Henttu P., Autio-Harmainen H., Soini Y., Vihko R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using Northern blot analysis, in situ hybridization and immunochemical stainings with monoclonal and bispecific antibodies. Int. J. Cancer. 1993, 55:590-597.
84. Vihko P. Characterization of the principal human prostatic acid phosphatase isoenzyme, purified by affinity chromatography and isolectric focusing Part II. Clin. Chem. 1978, 24:1783-1787.
85. Vihko P., Kontturi M., Korhonen L.K. Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I. Clin. Chem. 1978, 24:466-470.
86. Rönnberg L., Vihko P., Sajanti E., Vihko R. Clomiphene citrate administration to normogonadotropic subfertile men: Blood hormone changes and activation of acid phosphatase in seminal fluid. Int. J. Androl. 1981, 4:372-378.
87. Apostol I., Kuciel R., Wasylewska E., Ostrowski W.S. Phosphotyrosine as a substrate of acid and alkaline phosphatases. Acta Biochem. Pol. 1985, 32:187-197.
88. Vihko P., Kurkela R., Porvari K., Herrala A., Lindfors A., Lindqvist Y., Schneider G. Rat acid phosphatase: Overexression of active secreted enzyme by recombinant baculovirus-infected insect cells, molecular properties and crystallization. Proc. Natl Acad. Sci. USA 1993, 90:799-803.
89. Dziembor-Gryszkiewicz E., Fikus M., Kazimierczuk Z., Ostrowski W. Activity of human prostatic acid phosphatase toward purine 5?-phosphonucleosides. Bull. Acad. Pol. Sci. Biol. 1978, 26:815-821.
90. Wasylewska E., Czubak J., Ostrowski W.S. Phosphoprotein phosphatase activity of human prostate acid phosphatase. Acta. Biochim. Pol. 1983, 30:175-184.
91. Li H.X., Chernoff J., Chen L.B., Kirschonbaum A. A phosphotyrosyl-protein activity associated with acid phosphatase from human prostate gland. Eur. J. Biochem. 1984, 138:45-51.
92. Winqvist R., Virkkunen P., Grzeschik K.H., Vihko P. Chromosomal localization to 3q21?qter and two Taql RFLPs of the human prostae-specific acid phosphatase gene (ACCP). Cytogenet. Cell. Genet. 1989, 52:68-71.
93. Virkkunen P., Hedberg P., Palvino J., Birr E., Porvari K., Ruokonen M., Taavitsainen P., Jänne O., Vihko P. Structure comparison of human and rat prostate-specific acid phosphatase genes and their promoters: identification of putative androgen response elements. Biochem. Biophys. Res. Comm. 1994, 202:49-57.
94. Sharief F.S., Li S.S.L. Structure of human prostatic acid phosphatase gene. Biochem. Biophys. Res. Comm. 1992, 184:1468-1476.
95. Vihko P., Virkkunen P., Henttu P., Roiko K., Solin T., Huhtala M.L. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 1988, 236:275-281.
96. Schneider G., Lindqvist Y., Vihko P. Three-dimensional structure of rat acid phosphatase. EMBO J. 1993, 12:2609-2615.
97. Davidson R.E. Structural aspects of human prostatic acid phosphatase and fast atom bombardment mass spectrometric analysis of E. coli L-threonine deaminase. Ph.D. thesis 1990, Purdue University, West Lafayette, IN.
98. Mctigue J.J., van Etten R.L. An essential arginine residue in human prostatic acid phosphatase. Biochim. Biophys. Acta 1978, 523:422-429.
99. Saini M.S., van Etten R.L. An essential carboxylic acid group in human prostate acid phosphatase. Biochim. Biophys. Acta. 1979, 568:370-376.
100. van Etten R.L. Human prostatic acid phosphatase: a histidine phosphatase. Ann N. Y. Acad. Sci. 1982, 390:27-51.
101. Ostanin K., Saeed A., van Etten R.L. Heterologous expression of human prostatic acid phosphatase and site-directed mutagenesis of the enzyme active site. J. Biol. Chem. 1994, 269:9680-9684.
102. Van Etten R.L., Davidson R., Stevis P.E., MacArthur H., Moore D.L. Covalent structure, disulfide bonding, and identification reactive surface and active site residues of human prostatic acid phosphatase. J. Biol. Chem. 1991, 266:2313-2319.
103. Lindqvist Y., Schneider G., Vihko P. Crystal structure of rat acid phosphatase complexed with the transition-state analogs vanadate and molybdate. Implications for the reaction mechanism. Eur. J. Biochem. 1994, 221:139-142.
104. Lindqvist Y., Schneider G., Vihko P. Three-dimensional structure of rat acid phosphatase in complex with L(+)-tartrate. J. Biol. Chem. 1993, 268:20744-20746.
105. Zhang Z., Ostanin K., van Etten R.L. Covalent modification and site-directed mutagenesis of an active site tryptophan on human prostatic acid phosphatase. Acta. Biochim. Pol. 1997, 44:659-672.
106. Kuciel R., Bakalova A., Mazurkiewicz A., Bilska A., Ostrowski W. Is the subunit of prostatic acid phosphatase active? Reversible denaturation of prostatic acid phosphatase. Biochem. Int. 1990, 22:329-334.
107. Porvari K.S., Herrala A.M., Kurkela R.M., Taavitsainen P.A., Lindqvist Y., Schneider G., Vihko P.T. Site-directed mutagenesis of prostatic acid phosphatase: catalytically important aspartic acid 258, substrate specificity, and oligomerization. J. Biol. Chem. 1994, 269:22642-22646.
108. Chu T.M., Wang M.C., Merrin C., Valenzuela L., Murphy G.P. Isoenzymes of human prostatic acid phosphatase. Ann. N.Y. Acad. Sci. 1978, 390:16-26.
109. Smith J.K., Whitby L.B. The heterogeneity of prostatic acid phosphatase. Biochim. Biophys. Acta 1968, 151:607-618.
110. Yam L.T. Clinical significance of the human prostatic acid phosphatase. Am. J. Med. 1974, 56:604-616.
111. Lam K.W., Li C.Y., Yam L.T., Smith R.S., Hacker B. Comparison of prostatic and nonprostatic acid phosphatase. Ann. N.Y. Acad Sci. 1982, 390:1-15.
112. Kamoshida S., Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum. Pathol. 1990, 21:1108-1111.
113. Vihko P. Human prostatic acid phosphatase. Purification of a minor enzyme and comparisons of the enzymes. Invest. Urol. 1979, 16:349-352.
114. Coffey D.S., Pienta K.J. New concepts of study in the control of normal and cancer growth of the prostate. Current Concepts and Approaches to the Study of Prostate Cancer 1987, 1-73. Alan R Liss, Inc., New York. D.S. Coffey, N. Bruchovsky, W.A. Gardner, M.I. Resnick, J.P. Karr (Eds.).
115. Gutman A.B., Gutman E.N. An acid phosphatase occurring in the serum of patients with metastasizing carcinoma of prostate gland. J. Clin. Invest. 1938, 17:473-478.
116. Choe B.K., Pontes E.J., Dong M.K., Rose N.R. Double-antibody immunoassay for human prostatic acid phosphatase. Clin. Chem. 1980, 26:1854-1959.
117. Griffiths J.C. Prostate-specific acid phosphatase: re-evaluation of radioimmunoassay in diagnosing prostatic disease. Clin. Chem. 1989, 26:433-436.
118. Vihko P., Kostama A., Jänne O., Sajanti E., Vihko R. Rapid radioimmunoassay for prostate-specific acid phosphatase in human serum. Clin. Chem. 1980, 26:1544-1547.
119. Lee H.J., Fillers W.S., Iyyengar M.R. Phosphocreatine, an intracellular high-energy compound, is found in the extracellular fluid of the seminal vesicles in mice and rats. Proc. Natl Acad. Sci. USA 1988, 85:7265-7269.
120. Saini M.S., Van Etten L.R. A clinical assay for prostatic acid phosphatase using choline phosphate as a substrate: comparison with thymolphthalein phosphate. Prostate 1981, 2:359-368.
121. Ek P., Malm J., Lilja H., Carlsson L., Ronquist G. Exogenous protein kinases, A and C, but not endogenous prostasome-associated protein kinase, phosphorylate semenogelins I and II from human semen. J. Androl. 2002, 23:806-814.
122. Lin M.-F., Clinton G.M. The epidermal growth factor receptor from prostate cells is dephosphorylated by a prostate-specific phosphotyrosyl phosphatase. Mol. Cell Biol. 1988, 8:5477-5485.
123. Tanaka M., Kishi Y., Takanezawa Y., Kakehi Y., Aoki J., Arai H. Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett. 2004, 571:197-204.
124. Brillard-Bourdet M., Rehault S., Juliano L., Ferrer M., Moreau T., Gauthier F. Amidolytic activity of prostatic acid phosphatase on human semenogelins and semenogelin-derived synthetic substrates. Eur. J. Biochem. 2002, 269:390-395.
125. Boissonneault M., Chapdelaine A., Chevalier S. The enhancement by pervanadate of tyrosine phosphorylation of prostatic proteins occurs through the inhibition of membrane-associated tyrosine phosphatase. Mol. Cell Biochem. 1995, 153:139-144.
126. Guan K., Haun R.S., Watson S.J., Geahlen R.L., Dixon J.E. Cloning and expression of a protein-tyrosine-phosphatase. Proc. Natl Acad. Sci. USA 1990, 87:1501-1505.
127. Chernoff J., Schievella A.R., Jost C.A., Erikson R.L., Neel B.G. Cloning of a cDNA for a major human protein-tyrosine-phosphatase. Proc. Natl Acad. Sci. USA 1990, 87:2735-2739.
128. Meng T.C., Lee M.S., Lin M.F. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 2000, 19:2664-2677.
129. Lin M.F., Lee M.S., Zhou X.W., Andressen J.C., Meng T.C., Johansson S.L., West W.W., Taylor R.J., Anderson J.R., Lin F.F. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J. Urol. 2001, 166:1943-1950.
130. Vihko, P. (1993).
131. Sharma, S., Pirilä, P., Kaija, H., Porvari, K., Vihko, P., and Juffer, A. H. The oretical investigations of prostatic acid phosphatase. Proteins - structure, function and genetics (in press).
132. Lin M.F., Clinton G.M. Human prostatic acid phosphatase has phosphotyrosyl protein phosphatase activity. Biochem. J. 1986, 235:351-357.
133. Vihko P., Wahlberg L., Ehnholm C., Lukka M., Vihko R. Acid phosphatases bind to the main high densitylipoprotein apolipoprotein A-I. FEBS Lett. 1986, 202:309-313.
134. Neufeld E.B., Stonik J.A., Demosky S.J., Knapper C.L., Combs C.A., Cooney A., Comly M., Dwyer N., Blanchette-Mackie J., Remaley A.T., et al. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J. Biol. Chem. 2004, 279:15571-15578.
135. Aumüller G., Seitz J. Cytochemistry and biochemistry of acid phosphatases. VI: Immunoelectron microscopic studies on human prostatic and leucocytic acid phosphatases. Prostate 1985, 17:31-40.
136. Mori K., Wakasugi C. Immunocytochemical demonstration of prostatic acid phosphatase: different secretion kinetics between normal, hyperplastic and neoplastic prostate. J. Urol. 1985, 133:877-883.
137. Lilja H., Abrahamsson P.A. Three predominant proteins secreted by the human prostate gland. Prostate 1988, 12:29-38.
138. Sinha A.A., Gleason D.F., Wilson M.J., Wick M.R., Reddy P.K., Blackard C.E. Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the Gleason grading system. Prostate 1988, 13:1-15.
139. Lam K.W., Li Cy., Yam L.T., Sun T., Lee G., Ziesmer S. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989, 15:13-21.
140. Zeliavinski S., Comeau D., Lin M.F. Cloning and analysis of the promoter activity of the human prostatic acid phosphatase gene. Biochem. Biophys. Res. Commun. 1998, 245:108-112.
141. Zeliavinski S., Igawa T., Lim S., Taylor R., L.M.-F. Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter. Oncogene 2002, 21:3696-3705.
142. Shan J.D., Porvari K., Kivinen A., Patrikainen L., Halmetkytö M., Jänne J., Vihko P. Tissue-specific expression of the prostatic acid phosphatase promoter constructs. Biochem. Biophys. Res. Comm. 2003, 311:864-869.
143. Patrikainen L., Shan J., Porvari K., Vihko P. Identification of the DNA-binding site of a regulatory protein involved in prostate-specific and androgen receptor-dependent gene expression. Endocrinology 1999, 140:2063-2070.
144. Henttu P., Vihko P. Effect of tumor-promoting phorbol ester on androgen-regulated gene expression in prostatic LNCaP cells. In vitro Biology of Sex Steroid Hormone Action 1996, 384-395. Churchill Livingstone, Tokyo.
145. Horozewicz J., Leong S., Kawinski E., Karr J., Rosenthal H., Chu T., Mirand E., Murphy G. LNCaP model of human prostatic carcinoma. Cancer Res. 1983, 43:1809-1818.
146. Lin M.F., Garcia-Arenas R., Chao Y.C., Lai M., Patel P.C., Xia X.Z. Regulation of prostatic acid phosphatase expression and secretion by androgen in LNCaP human prostate carcinoma cells. Arch. Biochem. Biophys. 1993, 300:384-390.
147. Dulinska J., Laidler P., Labrfz M. Comparative analysis of prostatic acid phosphatase and prostate-specific antigen mRNA levels in hyperplastic prostate stimulated with steroid hormones and growth factors. Acta. Biochim. Pol. 2002, 49:357-368.
148. Henttu P., Liao S., Vihko P. Androgens up-regulate the human prostate-specific antigen mRNA but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 1992, 130:766-772.
149. Langler E.G., van Uffelen C.J., Blankenstein M.A., van Steenbrugge G.J., Mulder E. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 1993, 23:213-223.
150. Shan J.D., Porvari K., Ruokonen M., Karhu A., Launonen V., Hedberg P., Oikarinen J., Vihko P. Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein. Endocrinology 1997, 138:3764-3770.
151. Lin M.F., Zhang X.Q., Dean J., Lin F.-F. Protein kinase C pathway is involved in regulating the secretion of prostatic acid phosphatase in human prostate cancer cells. Cell Biol. Int. 2001, 25(11):1139-1148.